# Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer

> **NCT00138151** · PHASE2 · TERMINATED · sponsor: **University of Medicine and Dentistry of New Jersey** · enrollment: 33 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** recombinant interferon alpha-2b
- **DRUG:** isotretinoin
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00138151
- **Lead sponsor:** University of Medicine and Dentistry of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-03
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Slow accrual and lack of study drug
- **Last updated:** 2013-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138151, "Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00138151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*